> A CorpDev Partner is an experienced outside manager or entrepreneur, hired to realize a specific new business initiative he proposed. If he sets up the business within the agreed time, he stays on as its director. If he doesn't, he leaves. The initiative is usually something the organization has no internal ownership or expertise in: too new for the core business to expand into, too risky to justify its own P&L. The CorpDev Partner is a **risk buffer** and a **disruption driver**: he absorbs the risk of exploring the zone so the core doesn't have to, and pushes the organization toward it. The corporation isn't hiring an executive. It's underwriting an option, priced as a salary instead of a large budget, on one person's ability to convert outside expertise into a business it couldn't have built or bought alone. Taking on a CorpDev Partner is placing a bet on a potential internal founder. **Characteristics of this mechanism:** - an experienced manager, founder, or product leader. - unique ownership and knowledge of the initiative. - a fixed contract term, 6 to 18 months. - no, or very limited, budget, pooled case by case. - a formal mandate: authorization to pursue unconventional initiatives. **Placement within organization** A new "buffer" role with no fixed placement. These directors may sit inside the CorpDev function, inside a related business unit, or report directly to a C-suite sponsor: transformation, innovation, strategy, or the CEO. **Source of resources** Initially it's an option, paid from a disrupt budget: a small pool set aside for exploration, no revenue attached. If the initiative succeeds, that budget becomes a real P&L, which the director will run, and own where policy allows. ### What this is not It's a corporate adaptation of the VC venture-partner model, where an outsider brings deals to an already-diversified fund for carry or a fee, sometimes taking a board seat afterward. The corporate version differs: a disrupt budget caps how much disturbance these "directors-to-be" may cause, which caps how many a corporation can run at once. The payoff on success is an executive job, not carry. Nor is it internal intrapreneurship: the intrapreneur is a permanent employee proposing a venture from inside, still carrying its incentives and ceiling. The CorpDev Partner enters from outside, with no prior loyalty to the business. ### Compared to adjacent mechanisms | Criterion | CorpDev Partner | Internal R&D | Acquisition | | ------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------- | | **Choice trigger** | The Partner holds expertise, access, or conviction the organization cannot acquire elsewhere at the same risk level. | The opportunity sits within capabilities the organization already has. | The target already exists: buying it outright is faster or cheaper than building it. The organization is ready to own the P&L. | | **Cost to start** | The Partner's salary. | The funded cost of running the R&D stages. | Deal price, plus diligence and integration costs. | | **Risk** | None to the corporation in the ordinary sense: pre-structuring there's no investment to lose, only a bounded salary, closer to an insurance premium than a bet. | High. An internal team built under heavy organizational constraint, closer to a startup's risk of outright failure than to a funded business. | Lower than the price tag suggests: the target is already a mature, revenue-generating business. Doing nothing should preserve its P&L. | | **Commitment** | Wait and see. The trial exists to discover whether the opportunity is real before committing further. | Real and immediate: headcount and opex committed from day one. | Highest and immediate: purchase price, diligence, and integration cost, paid before value at scale is proven. All-in. | | **Dominant agency risk** | Deal-forcing bias: pressure to close something quickly, even a marginal deal. | Keep-alive bias: raising problems reads as failure, so a dying initiative gets kept going rather than killed. | Post-close bias: defending the bet by protecting projected synergies, sometimes past the point the numbers justify it. | | **Repeatability** | Low. Finding the right person is closer to a positive surprise than a pipeline. | High. Limited mainly by budget and appetite for risk. | Depends on target supply, not organizational capability; a serial acquirer can run this as a repeatable engine. | | **Failure mode** | The trial expires with no deal: a clean exit, sunk cost limited to salary. | The initiative proves unsuccessful and is closed, or starts slipping in priority or budget. Sunk cost limited to what was already spent. | Bad diligence or a failed integration destroys the value. Synergies never materialize. | A CorpDev Partner's work can end up producing an Internal R&D build or an Acquisition, a team assembled, or a company bought outright. The trial exists to mature the opportunity and cut its risk before either happens, which is also why the mandate shouldn't be grantable, or needed, once an opportunity is already decidable directly as R&D or M&A: if the organization could already choose confidently, it would just choose. It's the cheapest way to test a high-conviction, outside-sourced strategy before committing a team or a purchase price, popping the organization's strategic bubble by letting in an outsider whose job is to convince everyone, resource by resource, that the new business is worth building. ### Causes of failure 1. **The pitch was never specific enough to test.** A general direction ("look into fintech") instead of a named, checkable strategy gives the trial nothing concrete to fail against, and it quietly becomes a normal executive hire with an unusual title. 2. **Matrix starvation.** Lost competition for internal resources ruins the project timeline: no result, salary paid, but the hypothesis was never tested. 3. **Ambiguous accountability.** With no team or budget, it's hard to tell "blocked" from "not delivering." Without checkpoints, a weak trial can drift the full 18 months before anyone acts. 4. **Deal-forcing bias.** The payoff depends on closing something. The Partner over-invests in getting to any deal, marginal or not, rather than delivering the more valuable answer, "this doesn't work, stop." 5. **Post-success control disputes.** The management structure actually put in place may not match what the Partner expected, pushing him to leave right when the business was supposed to start paying off. Structure it as a project: a finite deadline, clear objectives, an officially granted interim title for matrix access, and exit terms, positive or negative, fixed before the trial starts. It's a good mechanism, but an upside and an enabler, not a planned pipeline, though a corporation can always keep a fixed number of seats open for it. ### Case illustration At the ICT group where I worked, this became a recurring, if never high-volume, practice: CorpDev Partners hired repeatedly over several years, each entering on a specific, named strategy, each given the same matrix-only, no-team, no-budget trial, each either converting into director of a new business line, with equity where policy allowed it, or leaving when the strategy didn't convert. It matured into a standing option in the corporate development toolkit, alongside M&A, joint ventures, and internal incubation. ### Related theory **Corporate entrepreneurship placement models.** [Wolcott & Lippitz (2007)](https://sloanreview.mit.edu/article/the-four-models-of-corporate-entrepreneurship/) map corporate entrepreneurship on two dimensions: organizational ownership (designated group versus diffused) and resource authority (a dedicated pool versus ad hoc access). The CorpDev Partner sits at the extreme corner of both before a deal: ownership diffused to one titled individual, resources entirely ad hoc. **Complementary assets.** [Teece (2006)](https://www.edegan.com/pdfs/Teeece%20(2006)%20-%20Reflections%20on%20profiting%20from%20innovation.pdf) argues that the innovator rarely captures an innovation's value alone; whoever controls the complementary assets, distribution, brand, capital, regulatory standing, captures the larger share. Here the corporation supplies those assets; the operator supplies the expertise it lacks. Structurally, it's a matching market for complementary assets, priced as an employment contract instead of a deal.